GENENTECH, INC for GENENTECH INC
What was lobbied
8 issue areas, each in the filer's own words, with who lobbied on it and where.
Food Industry (safety, labeling, etc.) FOO
Monitor and report on Food safety and supply chain issues;
| Lobbyist | Covered position, as disclosed |
|---|---|
| KATHERINE RAAB | Director |
Trade (domestic/foreign) TRD
Monitor issues related to export rules and regulations, international patent issues, WTO matters, the Trans-Pacific Partnership and other international issues impacting biotech and pharmaceuticals;
| Lobbyist | Covered position, as disclosed |
|---|---|
| DARIN GARDNER | Director |
| ELI KOGAN | Associate Direcctor |
Taxation/Internal Revenue Code TAX
Monitoring proposals on US tax treatment of foreign-owned U.S. corporations;
| Lobbyist | Covered position, as disclosed |
|---|---|
| DARIN GARDNER | — |
| ELI KOGAN | — |
Copyright/Patent/Trademark CPT
Patent Reform Act; general Patent reform issues; H.R.243 Patent Lawsuit Reform Act of 2011; H.R. 1249 Leahy-Smith America Invents Act S.23 - America Invents Act;
| Lobbyist | Covered position, as disclosed |
|---|---|
| DARIN GARDNER | Director |
| ELI KOGAN | Associate Direcctor |
Health Issues HCR
Advocacy related to ensuring access to necessary medicines; Proposed cuts to Part B reimbursement;Implementation of HR1 Medicare Prescription Drug and Modernization Act of 2003; Issues relating to PDUFA stimulus; Issues relating to comparative effectiveness and CMS coverage of FDA approved therapies; Issues related to the PPS rule involving stroke guidelines; implementation of the follow-on biologic provisions in P.L. 111-148-"Patient Protection and Affordable Care Act"; issues related to pandemic preparedness and macular degeneration; legislation on public health preparedness and response related to pandemic influenza; influenza Pandemic Preparedness federal state and local levels; advocate for approval of Avastin for late stage breast cancer; Implementation of the Affordable Care of Act of 2010
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID B BURT | Associate Direcctor |
| DARIN GARDNER | Director |
| EVAN MORRIS | Vice President |
| KATHERINE RAAB | Director |
Medicare/Medicaid MMM
Advocacy related ensuring access to necessary medicines; implementation of H.R. and Modernization Act of 2003; Issues relating to PDUFA, stimulus, issues relating comparative effectiveness and CMS coverage of FDA approved therapies; Medicare coverage and payment of Part B drugs and biologics; Support for H.R. 452 Medicare Decision Accountability Act of 2011 and S.668: "Health Care Bureaucrats Elimination Act"; FDA approval and enforcement issues,340B payment and implementation issues; Medicare issues; Monitor implementation of Medicare Pharmaceutical coverage and reimbursement 340B provisions of the Affordable Care Act
| Lobbyist | Covered position, as disclosed |
|---|---|
| DARIN GARDNER | Director |
| ELI KOGAN | Associate Direcctor |
| KATHERINE RAAB | Director |
Budget/Appropriations BUD
Issues related to pandemic preparedness and macular degeneration; FY12 Labor, HHS and Education Appropriation related to preparedness for pandemic influenza, HIV/AIDS programs, hepatitis screening and care: issues related to the budget and appropriations process; FY12 appropriations process, including H.R. 2112 and various continuing resolutions
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID B BURT | Associate Director |
| DARIN GARDNER | Director |
| EVAN MORRIS | VP |
Pharmacy PHA
Monitor drug safety; payment policies for prescription drugs; Prescription Drug User Free Act; advocacy related to ensuring access to necessary medicines
| Lobbyist | Covered position, as disclosed |
|---|---|
| DARIN GARDNER | — |
| EVAN MORRIS | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.